{
  "abstract": "Background Dysosmobacter welbionis is a recently discovered butyrate producer whose presence in stool correlates with improved metabolic health. Whether its abundance is reduced in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) remains unknown. Mechanistic insight into its butyrate production from myo -inositol, a dietary compound from fruits, beans, grains and nuts with metabolic benefits, is also limited. Objective To assess population-level distribution, relative abundance and strain diversity of D. welbionis in humans, and to elucidate its metabolic capacity to ferment myo -inositol into butyrate. Design We analysed several human cohorts for associations with liver health and evaluated D. welbionis J115 T supplementation in a diet-induced steatosis mouse model. An antibody-guided anaerobic cell-sorting strategy enabled isolation of distinct strains. We combined 13 C-labelled inositol isotopes with NMR, mass spectrometry, genomics and proteomics. Results We found that D. welbionis and two related species ( D. hominis and D. segnis ) are prevalent gut bacteria in the human gut. D. welbionis abundance was reduced in MASLD across two cohorts and inversely correlated with fibrosis score in a third cohort. Treatment with D. welbionis J115 T improved glycaemia and hepatic steatosis in high-fat diet fed mice. We identified a non-canonical myo -inositol-to-butyrate fermentation pathway. 19 human strains were isolated, comparative genomics of 23 strains revealed an open pangenome (about 2100 core genes) including the full myo- inositol fermentation pathway. Conclusion D. welbionis possesses a unique, conserved route to convert dietary myo -inositol into butyrate, distinguishing it from other commensals and supporting its potential as a next-generation probiotic for metabolic and liver health.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 26,
  "authors": [
    {
      "name": "Chi-Hsien Lee"
    },
    {
      "name": "Thi Phuong Nam Bui"
    },
    {
      "name": "Camille Petitfils"
    },
    {
      "name": "Ching Jian"
    },
    {
      "name": "Giselle Wong"
    },
    {
      "name": "Anthony Puel"
    },
    {
      "name": "Tiphaine Le Roy"
    },
    {
      "name": "Samuel Bellais"
    },
    {
      "name": "Bouthaina Ben Abdallah"
    },
    {
      "name": "Mélanie Nehlich"
    },
    {
      "name": "Thomas Leicht"
    },
    {
      "name": "Manyi Jia"
    },
    {
      "name": "Lesley Hoyles"
    },
    {
      "name": "Massimo Federici"
    },
    {
      "name": "Jose Manuel Fernández-Real"
    },
    {
      "name": "Remy Burcelin"
    },
    {
      "name": "Marc-Emmanuel Dumas"
    },
    {
      "name": "Nathalie Delzenne"
    },
    {
      "name": "Thomas Clavel"
    },
    {
      "name": "Sjef Boeren"
    },
    {
      "name": "Antonio Dario Troise"
    },
    {
      "name": "Andrea Scaloni"
    },
    {
      "name": "Giulio Muccioli"
    },
    {
      "name": "Willem de Vos"
    },
    {
      "name": "Matthias van Hul"
    },
    {
      "name": "Patrice Cani"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/czeskvq7dvtt1.bib",
  "cited_by": 11,
  "doi": "10.1136/gutjnl-2025-336617",
  "fulltext_url": null,
  "id": "czeskvq7dvtt1",
  "issns": [
    "0017-5749",
    "1468-3288"
  ],
  "landing_url": "https://hal.science/hal-05855888v1",
  "language": "en",
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "hal",
      "1.sdv.mhep"
    ],
    [
      "hal",
      "1.sdv.mp"
    ],
    [
      "hal",
      "2.sdv.mhep.em"
    ],
    [
      "openalex",
      "1312|Gut microbiota and health"
    ]
  ],
  "openalex": "W7119081926",
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-07-07",
  "publisher": "BMJ Publishing Group",
  "ris": "https://research.draconitic.com/paper/czeskvq7dvtt1.ris",
  "sources": [
    {
      "first_seen": "2026-11-07T12:20:26Z",
      "native_id": "hal-05855888",
      "source": "hal",
      "url": "https://hal.science/hal-05855888v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:1.sdv.mp",
      "subfield": "microbiology"
    },
    {
      "field": "medicine",
      "origin": "hal:2.sdv.mhep.em",
      "subfield": "endocrinology-metabolism"
    }
  ],
  "title": "Novel myo -inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health",
  "title_text": "Novel myo -inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health",
  "type": "peer-reviewed",
  "updated_at": "2026-11-09T12:20:29Z",
  "url": "https://research.draconitic.com/paper/czeskvq7dvtt1",
  "venue": "Gut",
  "versions": []
}